Alzheimer Disease, Amyloid beta-Protein

- Each subject / Healthy volunteer (HV) who meets the following criteria will be eligible for enrollment into the study:
 -- Is a man or woman and is > 55 of age, whereby females must be without childbearing potential (confirmed by either: age >/= 60; or history of hysterectomy, or last spontaneous bleeding at least 2 years prior to the study start)
 -- Has at least 6 years of education
 -- Is able to provide informed consent, understand the information provided on the purpose and conduct of the trial and to comply with study procedures
 -- Possesses a general health that permits adequate compliance with all study procedures
 -- The subject, or the subject and caregiver (for probable AD patients) will be compliant and have a high probability of completing the study
 -- Informed consent has been signed and dated (with time) by the subject and/or the subject's caregiver (for probable AD patients)
- Inclusion criteria for HV only:
 -- Has no evidence of cognitive impairment
 -- Has MRI brain scan that has been judged as "normal" (age- appropriate)
- Inclusion criteria for patients with AD only:
 -- Presents with positive assessment for dementia of Alzheimer's type
 -- Does not fulfill the criteria DLB or VaD
 -- MRI brain scan findings that do not reveal changes indicative of stroke and/or generalized cerebrovascular disease
 -- Has a caregiver that is willing and able to attend all study visits and perform the psychometric tests requiring the presence of a caregiver

- Has any contraindication to MRI examination scan
- Is scheduled for surgery and/or another invasive procedure within the time period of up to 24 hours following IMP application
- Is allergic to the IMP or any of its constituents and/or has a history of severe allergic reactions to drugs or allergens (e.g. patients / volunteers with allergic asthma)
- is critically ill and/or medically unstable and whose clinical course during the observation period is unpredictable
- Has a history of exposure to any radiation >15 mSv/year (e.g. occupational or radiation therapy)
- Is receiving drug therapy or other treatment that is known to lead to greatly fluctuating values of the hematological or chemical laboratory parameters or to severe side effects (e.g. chemotherapy)
- Has been previously enrolled in this study or participated in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening, and/or any radiopharmaceutical
- Has a brain tumor or other intracranial lesion, a disturbance of CSF circulation (e.g., normal pressure hydrocephalus) and/or a history of head trauma or brain surgery
- Has an inflammatory or infectious CNS disease, e.g. multiple sclerosis, HIV, syphilis, or Creutzfeldt-Jacob disease
- Has a history, physical, laboratory or imaging findings indicative of a neurological or psychiatric illness
- Has another disease that can cause disturbance of brain function (e.g. vitamin B12 or folic acid deficiency, disturbed thyroid function)
- Has a history of alcohol or drug abuse
- Has history of severe persistent depression